The diversity of vascular disease: A clinician’s perspective

Endothelial Cells in Health and Disease

Volumn , Issue , 2005, Pages 313-336

  Cooke, John P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80355138018     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (102)

1. Criqui MH. Peripheral arterial disease-epidemiological aspects. Vasc Med 2001; 6(3 Suppl): 3-7.
2. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286(11): 1317-1324.
3. Kannel WB. The Framingham study: its 50-year legacy and future promise. J Atheroscler Thromb 2000; 6(2): 60-66.
4. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324(17): 1149-1155.
5. Widmann MD, Sumpio BE. Lipoprotein (a): a risk factor for peripheral vascular disease. Ann Vasc Surg 1993; 7: 446-451.
6. Millonig G, Malcom GT, Wick G. Early inflammatory-immunological lesions in juvenile atherosclerosis from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY)-study. Atherosclerosis 2002; 160(2): 441-448.
7. Szuba A, Cooke JP. Thromboangiitis obliterans. An update on Buerger’s disease. West J Med 1998; 168(4): 255-260.
8. Adar R, Papa MZ, Halpern Z, Mozes M, Shoshan S, Sofer B, Zinger H, Dayan M, Mozes E. Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med 1983; 308(19): 1113-1116.
9. Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med 2000; 343(12): 864-869.
10. Numano F, Kobayashi Y, Maruyama Y, Kakuta T, Miyata T, Kishi Y. Takayasu arteritis: clinical characteristics and the role of genetic factors in its pathogenesis. Vasc Med 1996; 1(3): 227-233.
11. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS. Takayasu arteritis. Ann Intern Med 1994; 120(11): 919-929.
12. Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am J Pathol 1977; 86(3): 675-684.
13. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509.
14. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997; 96(10): 3264-3265.
15. Tsao PS, Buitrago R, Chan JR, Cooke JP. Fluid flow inhibits endothelial adhesiveness: nitric oxide and transcriptional regulation of VCAM-1. Circulation 1996; 94(7): 1682-1689.
16. Tsao PS, Wang B, Buitrago R, Shyy JY, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997; 96(3): 934-940.
17. Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM, Clowes AW. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 1992; 89(2): 507-511.
18. Casscells W, Hathorn B, David M, et al. Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis. Lancet 1996; 347: 1447-1449.
19. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001; 134(3): 224-238.
20. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999; 99(13): 1726-1732.
21. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo KM, Gillies S, Javaherian K, Folkman J. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003; 100(8): 4736-4741.
22. Heeschen C, Jang J, Hoai-Ky V, Kaji S, Yang P, Hu RS, Cooke JP. Nicotine is an agent of angiogenesis. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001; 7(7): 833-839.
23. Heeschen C, Weis M, Cooke JP. A novel angiogenic pathway mediated by nonneuronal nicotinic acetylcholine receptors. J Clin Invest 2002; 110(4): 527-536.
24. Jacobi J, Jang JJ, Sundram U, Fajardo L, Cooke JP. Nicotine stimulates wound healing in diabetic mice. Am J Pathol 2002; 161(1): 97-104.
25. Heeschen C, Weis M, Cooke JP. Nicotine promotes arteriogenesis. J Am Coll Cardiol 2003; 41(3): 489-496.
26. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7(4): 425-429.
27. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-1569.
28. Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99(19): 2503-2509.
29. Mann J, Davies MJ. Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 1999; 82: 265-268.
30. Liao JK, Bettmann MA, Sandor T, Tucker JI, Coleman SM, Creager MA. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res 1991; 68(4): 1027-1034.
31. Hiatt WR. Pharmacologic therapy for peripheral arterial disease and claudication. J Vasc Surg 2002; 36(6): 1283-1291.
32. American Heart Association. Heart Disease and Stroke Statistics--2003 Update. Dallas, TX.
33. Ouriel K. Acute limb ischemia. In: Rutherford RB, ed. Vascular Surgery. Philadelphia: W.B. Saunders Company, 2000: 813-821.
34. Davies PF, Shi C, Depaola N, Helmke BP, Polacek DC. Hemodynamics and the focal origin of atherosclerosis: a spatial approach to endothelial structure, gene expression, and function. Ann N Y Acad Sci 2001; 947: 7-16.
35. Weidinger FF, McLenachan JM, Cybulsky M, Gordon JM, Rennke HA, Hollenberg NK, Fallon JT, Ganz P, Cooke JP. Persistent dysfunction of regenerated endothelium following balloon angioplasty of rabbit iliac artery. Circulation 1990; 81(5): 1667-1679.
36. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA 1995; 92(24): 11190-11194.
37. Matsushita H, Chang E, Glassford AJ, Cooke JP, Chiu CP, Tsao PS. eNOS activity is reduced in senescent human endothelial cells: preservation by hTERT immortalization. Circ Res 2001; 89(9): 793-798.
38. McLenachan JM, Vita J, Fish DR, Treasure CB, Cox DA, Ganz P, Selwyn AP. Early evidence of endothelial vasodilator dysfunction at coronary branch points. Circulation 1990; 82(4): 1169-1173.
39. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 1997; 48: 489-509.
40. Stamler JS, Mendelsohn ME, Amarante P, Smick D, Andon N, Davies PF, Cooke JP, Loscalzo J. N-acetylcysteine potentates platelet inhibition by endothelium-derived relaxing factor. Circ Res 1989; 65(3): 789-795.
41. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Anti-atherogenic effects of l-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90(3): 1168-1172.
42. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994; 14(5): 753-759.
43. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E=endothelial nitric oxide synthase double-knockout mice. Circulation 2001; 104(4): 448-454.
44. Shimasaki Y, Yasue H, Yoshimura M, et al. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 1998; 31: 1506-1510.
45. 298 ! Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999; 100: 1515-1520.
46. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20(9): 2032-2037.
47. Boger R, Bode-Boger S, Szuba A, Tsao PS, Chan J, Tangphao O, Blaschke T, Cooke JP. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98(18): 1842-1847.
48. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99(9): 1141-1146.
49. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95(8): 2068-2074.
50. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-2128.
51. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358(9299): 2113-2117.
52. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, Whitley GS, Vallance P. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119(8): 1533-1540.
53. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99(24): 3092-3095.
54. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten H, Tornvall P. Mild to moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38(1): 111-116.
55. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. J Am Med Assoc 2002; 287(11): 1420-1426.
56. Stuhlinger MC, Tsao PS, Her J-H, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the NO synthase pathway--role of asymmetric dimethylarginine. Circulation 2001; 104(21): 2569-2575.
57. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Ogawa T, Reaven G, Cooke JP. Dysregulation of dimethylarginine dimethylaminohydrolase: A mechanism for endothelial dysfunction in diabetes mellitus. Circulation 2002; 106(8): 987-992.
58. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343 Pt 1: 209-214.
59. Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, Marsden PA. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol 1997; 17(11): 2479-2488.
60. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. J Thorac Cardiovasc Surg 1985; 89(2): 248-258.
61. Luscher TF, Diederich D, Siebenmann R, Lehmann K, Stulz P, von Segesser L, Yang ZH, Turina M, Gradel E, Weber E, et al. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 1988; 319(8): 462-467.
62. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316(22): 1371-1375.
63. Hertzer NR. Basic data concerning associated coronary artery disease in peripheral vascular patients. Ann Vasc Surg 1987; 1: 616-620.
64. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years in an academic hospital-based geriatrics practice. J Am Geriatr Soc 1999; 47: 1255-1256.
65. Wilt TJ, Davis BR, Meyers DG, Rouleau JL, Sacks FM. Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240mg=dL: baseline results from Cholesterol and Recurrent Events (CARE) study. Angiology 1996; 47: 533-541.
66. Violi F, Criqui M, Longoni A, Castiglioni C. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. study. Atherosclerosis 1996; 120(1-2): 25-35.
67. Cooke JP. The pathophysiology of peripheral arterial disease: rational targets for drug intervention. Vasc Med 1997; 2(3): 227-230.
68. McDermott MM, Mehta S, Greenland P. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001; 286(13): 1599-1606.
69. Fuster V, Corti R, Badimon JJ. Therapeutic targets for the treatment of atherothrombosis in the new millennium-clinical frontiers in atherosclerosis research. Circ J 2002; 66(9): 783-789.
70. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001; 134(3): 224-238.
71. Schnieder FA, Comerota AJ. Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. Am J Cardiol 2001; 87(supp1): 30-130.
72. Dieter RS, Chu WW, Pacanowski JP, McBride PE, Tanke TE. The significance of lower extremity peripheral arterial disease. Clin Cardiol 2002; 25: 3-10.
73. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet J, Tedgui A. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-353.
74. Badimon JJ, Lettino M, Toschi V, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of TFPI on plaque thrombogenicity under flow conditions. Circulation 1999; 14: 1780-1787.
75. Luscher TF, Cooke JP, Houston DS, Neves RJ, Vanhoutte PM. Endothelium-dependent relaxation in human arteries. Mayo Clin Proc 1987; 62(7): 601-606.
76. Cohen RA, Shepherd JT, Vanhoutte PM. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science 1983; 221(4607): 273-274.
77. Vanhoutte PM, Miller VM. Heterogeneity of endothelium-dependent responses in mammalian blood vessels. J Cardiovasc Pharmacol 1985; 7(suppl 3): S12-S23.
78. Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity 2002; 16(1): 1-4.
79. Geary RL, Wong JM, Rossini A, Schwartz SM, Adams LD. Expression profiling identifies 147 genes contributing to a unique primate neointimal smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol 2002; 22(12): 2010-2016.
80. Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
81. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000; 133(2): 81-91.
82. Breslow JL. Genetics of lipoprotein abnormalities associated with coronary artery disease susceptibility. Annu Rev Genet 2000; 34: 233-254.
83. Leeson CP, Hingorani AD, Mullen MJ, Jeerooburkhan N, Kattenhorn M, Cole TJ, Muller DP, Lucas A, Humphries SE, Deanfield JE. Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res 2002; 90(11): 1153-1158.
84. Myers RH, Kiely DK, Cupples LA, Kannel WB. Parental history is an independent risk factor for coronary artery disease: the Framingham study. Am Heart J 1990; 120(4): 963-969.
85. Sorensen, TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318: 727-732
86. Annu Rev Genet 2000; 34: 233-254.
87. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1(6): 445-466.
88. Kroon AA, Ajubi N, van Asten WN, Stalenhoef AF. The prevalence of peripheral vascular disease in familial hypercholesterolaemia. J Intern Med 1995; 238(5): 451-459.
89. Brugger D, Schuster H, Zollner N. Familial hypercholesterolemia and familial defective apolipoprotein B-100: comparison of the phenotypic expression ln 116 cases. Eur J Med Res 1996; 1(8): 383-386.
90. Risch NJ. Searching for genetic determinants in the new millennium. Nature 2000; 405(6788): 847-856.
91. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 1994; 330(15): 1041-1046.
92. Shimasaki Y, Yasue H, Yoshimura M, et al. Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 1998; 31: 1506-1510.
93. 298 ! Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999; 100: 1515-1520.
94. Ye S, Watts GF, Maldalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73: 209-215.
95. Humphries SE, Luong LA, Talmud PJ, et al. The 5A=6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lipid Coronary Angiography Trial. Atherosclerosis 1998; 139: 49-56.
96. Terashima M, Akita H, Kanazawa K, et al. Stromelysin promoter 5A=6A polymorphism is associated with acute myocardial infarction. Circulation 1999; 99: 2717-2719.
97. Samani NJ, Thompson JR, O’Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 1996; 94: 708-712.
98. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Sorensen TIA, Jensen G, Tybjaerg-Hansen A. ACE gene polymorphism: ischemic heart disease and longevity in 10 150 individuals: a case-referent and retrospective cohort study based on the Copenhagen City Heart Study. Circulation 1997; 95: 2358-2367.
99. Keavney B, McKenzie C, Parish S, et al. Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion=deletion polymorphism and myocardial infarction about 5000 cases and 6000 controls. Lancet 2000; 355: 434-442.
100. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273: 1516-1517.
101. Mann MJ, Gibbons GH, Tsao PS, von der Leyen H, Cooke JP, Buitrago R, Kernoff R, Dzau VJ. Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts. J Clin Invest 1997; 99(6): 1295-1301.
102. Mann MJ, Gibbons GH, Kernoff RS, Diet FP, Tsao PS, Cooke JP, Kaneda Y, Dzau VJ. Genetic engineering of vein grafts resistant to atherosclerosis. Proc Natl Acad Sci USA 1995; 92(10): 4502-4506.